JP2016526540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526540A5 JP2016526540A5 JP2016520439A JP2016520439A JP2016526540A5 JP 2016526540 A5 JP2016526540 A5 JP 2016526540A5 JP 2016520439 A JP2016520439 A JP 2016520439A JP 2016520439 A JP2016520439 A JP 2016520439A JP 2016526540 A5 JP2016526540 A5 JP 2016526540A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- alkylene
- compound
- oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 150000001204 N-oxides Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- BNUTZGKSWDKZME-UHFFFAOYSA-N C1(CC1)C1=C(C(=NN1CC1=C(C=C(C=C1F)OCC)F)C1=NC=C(C(=N1)NC1=CC=NC=C1)OCCCS(=O)(=N)C)C Chemical compound C1(CC1)C1=C(C(=NN1CC1=C(C=C(C=C1F)OCC)F)C1=NC=C(C(=N1)NC1=CC=NC=C1)OCCCS(=O)(=N)C)C BNUTZGKSWDKZME-UHFFFAOYSA-N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 125000005555 sulfoximide group Chemical group 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13173278 | 2013-06-21 | ||
| EP13173278.6 | 2013-06-21 | ||
| PCT/EP2014/062688 WO2014202583A1 (en) | 2013-06-21 | 2014-06-17 | Substituted benzylpyrazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526540A JP2016526540A (ja) | 2016-09-05 |
| JP2016526540A5 true JP2016526540A5 (OSRAM) | 2017-07-20 |
Family
ID=48651936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520439A Pending JP2016526540A (ja) | 2013-06-21 | 2014-06-17 | 置換ベンジルピラゾール |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160151370A1 (OSRAM) |
| EP (1) | EP3010902A1 (OSRAM) |
| JP (1) | JP2016526540A (OSRAM) |
| CN (1) | CN105452236A (OSRAM) |
| CA (1) | CA2916097A1 (OSRAM) |
| HK (1) | HK1222846A1 (OSRAM) |
| WO (1) | WO2014202583A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| JP6141866B2 (ja) | 2011-12-21 | 2017-06-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換ベンジルピラゾール類 |
| WO2014147204A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| EP3010901B1 (en) | 2013-06-21 | 2017-09-13 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP2016525076A (ja) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| WO2015063003A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| WO2015193339A1 (en) | 2014-06-17 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| US10350206B2 (en) | 2014-09-19 | 2019-07-16 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as BUB1 inhibitors |
| CN107406417B (zh) | 2015-01-28 | 2020-06-09 | 拜耳制药股份公司 | 4H-吡咯并[3,2-c]吡啶-4-酮衍生物 |
| CA2989469A1 (en) | 2015-06-17 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| WO2018234488A1 (en) | 2017-06-23 | 2018-12-27 | Basf Se | Substituted cyclopropyl derivatives |
| EP4217070A1 (en) | 2020-09-23 | 2023-08-02 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| JP2023548657A (ja) | 2020-10-09 | 2023-11-20 | スコーピオン セラピューティクス インコーポレイテッド | がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤 |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| WO2024254298A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| WO2024254266A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863282B2 (en) * | 2003-03-14 | 2011-01-04 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| WO2008141843A1 (en) * | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| EP2755948B1 (en) * | 2011-09-16 | 2016-05-25 | Bayer Intellectual Property GmbH | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
| CN103814029B (zh) * | 2011-09-23 | 2016-10-12 | 拜耳知识产权有限责任公司 | 取代的咪唑并哒嗪 |
| UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| JP6141866B2 (ja) * | 2011-12-21 | 2017-06-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換ベンジルピラゾール類 |
| EP3010911A1 (en) * | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
-
2014
- 2014-06-17 EP EP14730907.4A patent/EP3010902A1/en not_active Withdrawn
- 2014-06-17 CA CA2916097A patent/CA2916097A1/en not_active Abandoned
- 2014-06-17 CN CN201480042983.3A patent/CN105452236A/zh active Pending
- 2014-06-17 JP JP2016520439A patent/JP2016526540A/ja active Pending
- 2014-06-17 US US14/900,575 patent/US20160151370A1/en not_active Abandoned
- 2014-06-17 WO PCT/EP2014/062688 patent/WO2014202583A1/en not_active Ceased
- 2014-06-17 HK HK16110960.7A patent/HK1222846A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526540A5 (OSRAM) | ||
| JP2016525076A5 (OSRAM) | ||
| RU2410378C2 (ru) | Сульфоксиминзамещенные пиримидины в качестве ингибиторов cdk и/или vegf, их получение и применение в качестве лекарственных средств | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2016522232A5 (OSRAM) | ||
| JP2014513110A5 (OSRAM) | ||
| JP2015501833A5 (OSRAM) | ||
| JP2018535967A5 (OSRAM) | ||
| JP2015504067A5 (OSRAM) | ||
| JP2014521688A5 (OSRAM) | ||
| JP2016518328A5 (OSRAM) | ||
| JP2019535746A5 (OSRAM) | ||
| JP2016525075A5 (OSRAM) | ||
| JP2015508103A5 (OSRAM) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2016531126A5 (OSRAM) | ||
| JP2019524883A5 (OSRAM) | ||
| JP2020506951A5 (OSRAM) | ||
| JP2019510810A5 (OSRAM) | ||
| JP2015520143A5 (OSRAM) | ||
| JP2014193925A5 (OSRAM) | ||
| JP2014518544A5 (OSRAM) | ||
| JP2018534301A5 (OSRAM) | ||
| JP2019522055A5 (OSRAM) | ||
| JP2015512943A5 (OSRAM) |